- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04256434
A Bioavailability Study of NALDEBAIN ER Injection and Nalbuphine Injection in Healthy Volunteers.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Each subject in a cohort will be evaluated for study eligibility during the screening period, which is within 28 days prior to receiving the study drug (Day 1). Eligible subjects will be admitted into the study site on Day -1 and will be required to stay in clinical site for 5 (Cohort 1) or 2 nights (Cohort 2) for study procedures in each cohort. Eligible subjects will undergo additional eligibility assessments on Day -1 and those reconfirmed eligible will intramuscularly receive NALDEBAIN ER Injection (Cohort 1) or nalbuphine (Cohort 2) on Day 1.
The blood sampling timepoints for Cohort 1 will be at predose, 6, 12, 24, 48, 56, 64, 72, 80, 88, and 96 hours after dosing. Subjects will be discharged after the 96-hour blood sample and return to the clinical site for the sample collection at 120, 168, 216, 288 and 360 hours post dosing. The blood sampling timepoints for Cohort 2 will be predose, 5, 15, and 30 minutes postdose, and 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours postdose.
Subjects will return for a follow-up visit to complete safety evaluations for approximately 15 days after study drug administration in cohort 1; and 1 days after study drug administration in Cohort 2.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
California
-
Cypress, California, United States, 90630
- WCCT Global Inc.
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male or female, 18 to 55 years of age inclusive at the time of signing the informed consent form
- Body weight must be above 60 kg.
- Body Mass Index (BMI) 18 to 40 kg/m2
- In good health on the basis of medical history, physical examination, electrocardiogram, chest X-ray, and routine laboratory evaluations.
- If male, must agree to use contraception as detailed in Appendix 5 of this protocol during the treatment period until the final PK sample, and refrain from donating sperm for 90 days after the dosing.
If female, is not pregnant (see Appendix 5), not breastfeeding, and at least one of the following conditions applies:
Not a woman of childbearing potential (WOCBP) as defined in Appendix 5 OR A WOCBP who agrees to follow the contraceptive guidance in Appendix 5 during the treatment period until the last PK sample.
Vital signs (after 3 minutes resting in a semi-supine position) which are within the following ranges:
- Oral temperature between 35.0-37.5°C.
- Systolic blood pressure, 90-140 mm Hg.
- Diastolic blood pressure, 50-90 mm Hg.
- Pulse rate, 50-90 bpm.
- Respiratory rate, 12-20 bpm
- Oxyhemoglobin saturation, ≥95%
- Fasting blood glucose, <110 mg/dL.
- Able to communicate well with the investigator and comply with the requirements of the study.
Exclusion Criteria:
- Use of any prescription medications or over-the-counter, non-prescription preparations (including herbal preparations) within 2 weeks prior to study entry unless deemed acceptable by the Investigator (except up to 5 doses of ≤ 1000 mg of acetaminophen or ≤ 400 mg ibuprofen within this 2 weeks period).
- Alcohol or caffeine ingested within 72 hours prior to dosing.
- Significant illness within 2 weeks prior to dosing.
- Participation in any clinical investigation within 2 months prior to dosing or longer as required by local regulation.
- Donation or loss of more than 500 mL of blood within 3 months prior to dosing. Donation or loss of more than 250 mL of blood within 2 months prior to dosing.
- Documented history of cardiovascular disease.
- Documented history of gastrointestinal disease.
- Documented history of asthma or lung disease.
- Presence of liver disease or liver injury as indicated by an abnormal liver function profile such as aspartate aminotransaminase (AST), alanine aminotransferase (ALT), gamma-glutamyl transferase (gamma-GT), Alkaline Phosphatase, or Total Bilirubin at Screening. (value of AST or ALT above 3 times of the upper limit of the normal range; other items clinically significant abnormality judged by investigator).
- Presence of impaired renal function as indicated by abnormal creatinine or BUN values or abnormal urinary constituents at Screening. (value of creatinine or BUN beyond the range from -20% of the lower limit of the normal range to +20% of the upper limit of the normal range; other items clinically significant abnormality judged by investigator)
- Documented history of neurological disease.
- Documented history of psychiatric disease.
- Has a history of human immunodeficiency virus (HIV) antibody positive, or tests positive for HIV; has a history of hepatitis B surface antigen (HBsAg) or hepatitis C antibody (anti-HCV) positive, or tests positive for HBsAg or anti-HCV at Screening.
- A known hypersensitivity to nalbuphine or its analogs.
- History of drug or alcohol abuse within 12 months prior to dosing or positive test results for alcohol or drugs of abuse at Screening and admission.
- Permanent confinement to an institution.
- Pregnant or lactating women.
- Subject has received any investigational product within 30 days or 5 half-lives (whichever is longer) prior to the dosing day or is planning to participate in a clinical trial during the study period.
- Has preplanned surgery or procedures that would interfere with the conduct of the study
- Individuals are judged by the investigator to be undesirable subjects for other reasons.
- Is an employee of the investigator or study site, with direct involvement in the proposed study or other studies under the direction of that investigator or study site, as well as family members of the employees or the Investigator.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Dinabuphine sebacate
Each subject in cohort 1 will receive 150 mg Dinalbuphine sebacate (75 mg/mL x 2 mL) intramuscularly.
|
150 mg Dinalbuphine sebacate
Other Names:
|
Active Comparator: Nalbuphine HCl
Each subject in cohort 2 will receive 20 mg Nalbuphine (20 mg x 1 mL) intramuscularly.
|
20 mg Nalbuphine
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Bioavailability of nalbuphine after intramuscular injection of NALDEBAIN and Nalbuphine.
Time Frame: Cohort 1: From predose to 360 hours post dosing. Cohort 2 : From predose to 24 hours post dosing.
|
To evaluate the relative bioavailability of nalbuphine after intramuscular injection of NALDEBAIN and Nalbuphine.
|
Cohort 1: From predose to 360 hours post dosing. Cohort 2 : From predose to 24 hours post dosing.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Maximum plasma concentration (Cmax) of nalbuphine, sebacoyl mononalbuphine ester (SME) and dinalbuphine sebacate.
Time Frame: Cohort 1: From predose to 360 hours post dosing. Cohort 2 : From predose to 24 hours post dosing.
|
Cmax for NALDEBAIN and Nalbuphine.
|
Cohort 1: From predose to 360 hours post dosing. Cohort 2 : From predose to 24 hours post dosing.
|
Tmax of nalbuphine, sebacoyl mononalbuphine ester (SME) and dinalbuphine sebacate.
Time Frame: Cohort 1: From predose to 360 hours post dosing. Cohort 2 : From predose to 24 hours post dosing.
|
Tmax for NALDEBAIN and Nalbuphine.
|
Cohort 1: From predose to 360 hours post dosing. Cohort 2 : From predose to 24 hours post dosing.
|
AUCinf of nalbuphine, sebacoyl mononalbuphine ester (SME) and dinalbuphine sebacate.
Time Frame: Cohort 1: From predose to 360 hours post dosing. Cohort 2 : From predose to 24 hours post dosing.
|
AUCinf for NALDEBAIN and Nalbuphine.
|
Cohort 1: From predose to 360 hours post dosing. Cohort 2 : From predose to 24 hours post dosing.
|
AUClast of nalbuphine, sebacoyl mononalbuphine ester (SME) and dinalbuphine sebacate.
Time Frame: Cohort 1: From predose to 360 hours post dosing. Cohort 2 : From predose to 24 hours post dosing.
|
AUClast for NALDEBAIN and Nalbuphine.
|
Cohort 1: From predose to 360 hours post dosing. Cohort 2 : From predose to 24 hours post dosing.
|
Elimination half-life (t1/2) of nalbuphine, sebacoyl mononalbuphine ester (SME) and dinalbuphine sebacate.
Time Frame: Cohort 1: From predose to 360 hours post dosing. Cohort 2 : From predose to 24 hours post dosing.
|
Elimination half-life for NALDEBAIN and Nalbuphine.
|
Cohort 1: From predose to 360 hours post dosing. Cohort 2 : From predose to 24 hours post dosing.
|
Total body clearance of the drug from plasma (CL) of nalbuphine, sebacoyl mononalbuphine ester (SME) and dinalbuphine sebacate.
Time Frame: Cohort 1: From predose to 360 hours post dosing. Cohort 2 : From predose to 24 hours post dosing.
|
Total body clearance for NALDEBAIN and Nalbuphine.
|
Cohort 1: From predose to 360 hours post dosing. Cohort 2 : From predose to 24 hours post dosing.
|
Volume of distribution (Vd) of nalbuphine, sebacoyl mononalbuphine ester (SME) and dinalbuphine sebacate.
Time Frame: Cohort 1: From predose to 360 hours post dosing. Cohort 2 : From predose to 24 hours post dosing.
|
Volume of distribution for NALDEBAIN and Nalbuphine.
|
Cohort 1: From predose to 360 hours post dosing. Cohort 2 : From predose to 24 hours post dosing.
|
Incidence and severity of adverse events (AEs)
Time Frame: Cohort 1: From predose to 360 hours post dosing. Cohort 2 : From predose to 24 hours post dosing.
|
To evaluate the systemic and local safety and tolerance.
|
Cohort 1: From predose to 360 hours post dosing. Cohort 2 : From predose to 24 hours post dosing.
|
Number of subjects with AEs
Time Frame: Cohort 1: From predose to 360 hours post dosing. Cohort 2 : From predose to 24 hours post dosing.
|
To evaluate number of subjects with adverse events.
|
Cohort 1: From predose to 360 hours post dosing. Cohort 2 : From predose to 24 hours post dosing.
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: David Nguyen, MD, WCCT Global
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- LT1001-104
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Health
-
BIO-CAT Microbials, LLCBiofortis Clinical Research, Inc.CompletedImmune Health | Cardiovascular Health | Gastrointestinal Health | Digestive HealthUnited States
-
Holbaek SygehusRecruitingHealth Behavior | Health Knowledge, Attitudes, Practice | Health-Related Behavior | Health LiteracyDenmark
-
Ankara Yildirim Beyazıt UniversityNot yet recruitingHealth Attitude | Health Behavior | Health KnowledgeTurkey
-
BIO-CAT Microbials, LLCOhio State University; Biofortis Clinical Research, Inc.CompletedImmune Health | Gastrointestinal Health | Digestive HealthUnited States
-
Oregon Health and Science UniversityFederal Emergency Management Agency; National Fallen Firefighters FoundationCompletedHealth Behavior | Occupational Health | Total Worker HealthUnited States
-
Scripps HealthCompletedHealth Attitude | Health Behavior | Health Knowledge, Attitudes, PracticeUnited States
-
Laboratoire Interuniversitaire de Biologie de la...CompletedHealth, Subjective | Health Behavior | Health Knowledge, Attitudes, PracticeFrance
-
VA Office of Research and DevelopmentCompletedMental Health | Veterans Health | Rural HealthUnited States
-
UMC UtrechtCompletedCardiovascular Health | Metabolic Health | Pulmonary HealthNetherlands
-
Istanbul University - Cerrahpasa (IUC)CompletedHealth Risk Behaviors | Reproductive Health | Sexual HealthTurkey
Clinical Trials on Dinalbuphine sebacate
-
Tri-Service General HospitalNot yet recruitingCaesarean Section | Analgesia | Post Operative Pain
-
E-DA HospitalRecruitingObesity | Pain, Postoperative | Pharmacokinetics | Pain, Chronic | Bariatric SurgeryTaiwan
-
E-DA HospitalCompletedQuality of Life | Pain, Postoperative | Cholecystitis | Pain, ChronicTaiwan
-
Mackay Memorial HospitalRecruitingPostoperative Pain | Caesarean Section | AnalgesiaTaiwan
-
Li-Jen HsinNot yet recruitingPain, Postoperative | Pain, Acute | Obstructive Sleep Apnea-hypopnea Syndrome
-
China Medical University HospitalNot yet recruitingPostoperative Pain | Lung Cancer | Lung Tumor
-
Lumosa Therapeutics Co., Ltd.CompletedPain | Analgesia DisorderTaiwan
-
E-DA HospitalNot yet recruitingCesarean Section | Post Operative Pain, Acute | Post Operative Pain, ChronicTaiwan
-
Dalin Tzu Chi General HospitalNot yet recruitingCesarean Section | Postsurgical Pain | Chronic Post-surgical Pain
-
Kaohsiung Medical University Chung-Ho Memorial...RecruitingAnalgesia | Satisfaction, Patient | Itching | Injection Site Reaction | Nausea and Vomiting, PostoperativeTaiwan